Roisin O'Cearbhaill, MD, discusses the safety and efficacy of TPIV200 vs GM-CSF alone in patients with high-grade, platinum-sensitive ovarian cancer.
Hope S. Rugo, MD, discusses the OS findings of 2 trials examining ribociclib plus endocrine therapy for advanced breast cancer and visceral metastases.
Dr Tykodi shares data analyses of cohort A from the KEYNOTE-427 trial on first-line pembrolizumab for clear cell renal cell carcinoma, presented in two abstracts at the virtual 2020 ASCO Annual…
Ghassan Abou-Alfa, MD, discusses systemic and local therapy updates in hepatocellular carcinoma in the third part of this interview highlighting abstracts of note presented at the virtual 2020 ASCO…
Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, discusses results from the phase 1 Alexander study, which evaluated AUTO3 plus pembrolizumab in relapsed/refractory DLBCL.
Claire Verschraegen, MD, comments on a phase 2 study examining the use of chemotherapy with durvalumab in patients with pleural mesothelioma.
Dr Penson provides an overview of the latest evidence-based data regarding surgical and pharmacologic ovarian cancer treatment that were presented at ASCO 2020.
Stay in the know.
OncNet Newsletter